OWA
ANIP icon

Opal Wealth Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

Opal Wealth Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-367
Closed -$28.2K – 246
2026
Q1 		$28.2K Buy
+367
New +$28.6K 0.01% 525
2025
Q3 		– Sell
-377
Closed -$24.6K – 215
2025
Q2 		$24.6K Buy
377
+12
+3% +$781 0.01% 522
2025
Q1 		$24.4K Buy
+365
New +$21.8K 0.01% 492

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opal Wealth Advisors's ANIP Position: Q2 2026 in Review

Opal Wealth Advisors sold out of ANI Pharmaceuticals (ANIP) in Q2 2026, closing a stake of 367 shares — an estimated $28.2K sold.

Opal Wealth Advisors first reported a position in ANIP in Q1 2025 and held it in 3 quarters. The position peaked at $28.2K in Q1 2026. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Opal Wealth Advisors reported no remaining ANI Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Opal Wealth Advisors sold 367 ANI Pharmaceuticals shares in Q2 2026, an estimated $28.2K.
  • Opal Wealth Advisors first reported a position in ANI Pharmaceuticals in Q1 2025 and held it in 3 quarters.
  • Opal Wealth Advisors's ANI Pharmaceuticals position peaked at $28.2K in Q1 2026.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Opal Wealth Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.